- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.
EP: 1.Fixed-Duration Options for CLL
EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study
EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
EP: 4.Sequencing Considerations in Relapsed/Refractory CLL
EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
EP: 8.Switching Between BTK Inhibitors in CLL
Video content above is prompted by the following:
- What key factors influence your decision when selecting among the available BTK inhibitors for patients with R/R CLL?
- What clinical or molecular features help identify patients with R/R CLL who are most likely to benefit from noncovalent BTK inhibitors compared with covalent BTK inhibitors?
Patient Care Experience Declines After Private Equity Hospital Acquisitions
January 31st 2025Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.
Read More
